CLINICAL PROTOCOL: A PHASE 2, PLACEBO CONTROLLED, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BMS-986141 FOR THE PREVENTION OF RECURRENT BRAIN INFARCTION IN SUBJECTS RECEIVING ACETYLSALICYCLIC ACID (ASA) FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK
- Registry ID
- CV006004
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Last update
- 2016-02-16
Conditions
- ISCHEMIC ATTACK AND MINOR STROKE
Related clinical trials
- NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY
- FOCAL CEREBRAL ARTERIOPATHY STEROID (FOCAS) TRIAL
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
- RANDOMIZED EFFICACY AND SAFETY TRIAL WITH ORAL S 44819 AFTER RECENT ISCHEMIC CEREBRAL EVENT INTERNATIONAL, MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY
- A RANDOMIZED CONTROLLED TRIAL OF TNK-TPA VERSUS STANDARD OF CARE FOR MINOR ISCHEMIC STROKE WITH PROVEN OCCLUSION
- PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) TRIAL, A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER CLINICAL TRIAL
View on source registry